CymitQuimica logo

CAS 1019206-88-2

:

Regorafenib hydrate

Description:
Regorafenib hydrate is a small-molecule tyrosine kinase inhibitor primarily used in the treatment of various cancers, including colorectal cancer and gastrointestinal stromal tumors. It functions by inhibiting multiple kinases involved in tumor growth and angiogenesis, thereby disrupting the signaling pathways that promote cancer progression. The substance is characterized by its complex structure, which includes a pyridine ring and a phenyl group, contributing to its pharmacological activity. Regorafenib hydrate is typically administered orally and is known for its moderate solubility in water, which is enhanced in its hydrate form. The hydrate form is significant as it can influence the drug's stability, solubility, and bioavailability. Common side effects associated with regorafenib include fatigue, diarrhea, and hypertension, reflecting its systemic effects on both cancer cells and normal tissues. As with many targeted therapies, careful monitoring is essential to manage potential adverse effects and ensure optimal therapeutic outcomes.
Synonyms:
  • Regorafenib monohydrate
Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.